Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BON Bon Natural Life	$1.38 +0.0%	$1.39	$1.14 ▼ $73.75	$230K	-0.47	1.77 million shs	47,873 shs
PBLA Panbela Therapeutics	$0.16	$0.19	$0.05 ▼ $0.47	$767K	1.33	16,227 shs	501 shs
PTPI Petros Pharmaceuticals	$0.03 -1.8%	$0.03	$0.02 ▼ $16.25	$857K	1.56	4.98 million shs	260,246 shs
SRNE Sorrento Therapeutics	$0.00 -24.6%	$0.00	$0.00 ▼ $0.02	$2.37M	0.85	121,918 shs	70,004 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BON Bon Natural Life	+6.15%	+6.15%	-4.17%	-23.33%	-97.41%
PBLA Panbela Therapeutics	0.00%	0.00%	0.00%	-33.40%	-56.38%
PTPI Petros Pharmaceuticals	-2.37%	-7.10%	+5.88%	-26.15%	-99.67%
SRNE Sorrento Therapeutics	+18.75%	-10.94%	+338.46%	+338.46%	-43.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BON Bon Natural Life	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PBLA Panbela Therapeutics	0.8318 of 5 stars	0.0	5.0	0.0	0.0	2.8	0.0	0.0
PTPI Petros Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SRNE Sorrento Therapeutics	0.716 of 5 stars	0.0	2.0	0.0	4.3	0.0	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
BON Bon Natural Life	N/A	N/A	N/A
PBLA Panbela Therapeutics	N/A	N/A	N/A
PTPI Petros Pharmaceuticals	N/A	N/A	N/A
SRNE Sorrento Therapeutics	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BON Bon Natural Life	$23.84M	0.01	$1.77 per share	0.78	$37.78 per share	0.04
PBLA Panbela Therapeutics	N/A	N/A	N/A	N/A	($18.37) per share	N/A
PTPI Petros Pharmaceuticals	$5.11M	0.17	N/A	N/A	$4.04 per share	0.01
SRNE Sorrento Therapeutics	$60.32M	0.04	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BON Bon Natural Life	$400K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PBLA Panbela Therapeutics	-$25.26M	-$71.13	N/A	∞	N/A	N/A	N/A	-302.61%	N/A
PTPI Petros Pharmaceuticals	-$8.16M	-$52.91	N/A	∞	N/A	N/A	-78.22%	-23.50%	N/A
SRNE Sorrento Therapeutics	-$572.84M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BON Bon Natural Life	N/A	N/A	N/A	N/A	N/A
PBLA Panbela Therapeutics	N/A	N/A	N/A	N/A	N/A
PTPI Petros Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRNE Sorrento Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BON Bon Natural Life	0.02	2.42	2.32
PBLA Panbela Therapeutics	N/A	0.26	0.26
PTPI Petros Pharmaceuticals	1.58	0.85	0.74
SRNE Sorrento Therapeutics	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BON Bon Natural Life	0.57%
PBLA Panbela Therapeutics	4.37%
PTPI Petros Pharmaceuticals	12.34%
SRNE Sorrento Therapeutics	0.02%

Insider Ownership

Company	Insider Ownership
BON Bon Natural Life	26.48%
PBLA Panbela Therapeutics	0.01%
PTPI Petros Pharmaceuticals	8.23%
SRNE Sorrento Therapeutics	2.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BON Bon Natural Life	100	167,000	863,000	Not Optionable
PBLA Panbela Therapeutics	6	4.86 million	4.86 million	Not Optionable
PTPI Petros Pharmaceuticals	20	31.16 million	9.93 million	Not Optionable
SRNE Sorrento Therapeutics	800	551.28 million	536.95 million	No Data

BON, PTPI, SRNE, and PBLA Headlines

Recent News About These Companies

Sorrento Therapeutics Inc (SRNE) - Investing.com

July 3, 2025 | investing.com

SRNE Sorrento Therapeutics, Inc. - Seeking Alpha

June 29, 2025 | seekingalpha.com

Sorrento Therapeutics Stock Price, Quotes and Forecasts | OTC:SRNE | Benzinga

April 19, 2025 | benzinga.com

Sorrento Shareholders Lose Discovery Bid Over Judge Relationship

March 28, 2025 | news.bloomberglaw.comN

Scilex says bankruptcy court extends lockup period on shares of Scilex dividend

January 31, 2025 | markets.businessinsider.com

DSI Introduces Westbury Sorrento Aluminum Railing with Bold Distinctive Mesh Stainless Steel Infills

October 24, 2024 | newsfilecorp.comN

Sorrento enrols 60 of 80-patient Phase II target for abivertinib in Covid-19; futility analysis potentially in a month, CEO says

August 20, 2024 | msn.com

Sorrento Resources to Sell Three Newfoundland Properties to Gold Hunter

May 29, 2024 | newsfilecorp.comN

Sorrento Therapeutics Inc (SRNE)

May 25, 2024 | investing.com

Sorrento Resources Announces Appointment of Alex Bugden as a Director and Qualified Person

May 8, 2024 | newsfilecorp.comN

DSI Introduces Westbury(R) Sorrento Aluminum and Stainless Steel Mesh Railing

May 1, 2024 | newsfilecorp.comN

Sorrento Therapeutics Inc SRNE

April 26, 2024 | morningstar.comM

Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks

March 27, 2024 | news.bloomberglaw.comN

Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks

March 27, 2024 | news.bloomberglaw.comN

Sorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1)

March 12, 2024 | news.bloomberglaw.comN

Judge Declines to Dismiss Sorrento Therapeutics Bankruptcy Case

March 12, 2024 | wsj.com

Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

February 27, 2024 | tmcnet.com

Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

February 27, 2024 | businesswire.com

Sorrento Therapeutics

February 7, 2024 | pharmaphorum.comP

5 Sanders Cove, Sorrento WA 6020

January 18, 2024 | domain.com.auD

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BON, PTPI, SRNE, and PBLA Company Descriptions

Bon Natural Life NYSE:BON

$1.38 +0.00 (+0.01%)

Closing price 03:59 PM Eastern

Extended Trading

$1.38 +0.00 (+0.36%)

As of 07:13 PM Eastern

Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. It offers personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; and natural health supplements comprising powder drinks and bioactive food ingredient products used as food additives and nutritional supplements. Its products are used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is based in Xi'an, the People's Republic of China.

Panbela Therapeutics NASDAQ:PBLA

$0.16 0.00 (0.00%)

As of 08/21/2025 11:24 AM Eastern

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Petros Pharmaceuticals NASDAQ:PTPI

$0.03 0.00 (-1.79%)

As of 03:54 PM Eastern

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Sorrento Therapeutics NASDAQ:SRNE

$0.0043 0.00 (-24.56%)

As of 03:59 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time